Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2445606 | 0.87 | NPSR1 (0.46) | NPSR1CHRM1HSD11B1LMNAIDH1 | |
| SCHEMBL11156458 | 0.84 | — | — | |
| SCHEMBL12302983 | 0.80 | ALDH1A1 (0.37) | LMNAMAPT | |
| SCHEMBL2451039 | 0.80 | NPSR1 (0.46) | NPSR1CHRM1HSD11B1LMNAIDH1 | |
| SCHEMBL19271800 | 0.78 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNAIDH1 | |
| SCHEMBL12302197 | 0.78 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNAIDH1 | |
| SCHEMBL16099826 | 0.78 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNAIDH1 | |
| SCHEMBL646389 | 0.78 | CHRM1 (0.41) | NPSR1CHRM1HSD11B1LMNAIDH1 | |
| SCHEMBL15116519 | 0.78 | ALDH1A1 (0.30) | — | |
| SCHEMBL705019 | 0.78 | NPSR1 (0.40) | NPSR1CHRM1HSD11B1LMNAIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090892-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 2025-05-01 | — | — | WO | claimed |
| US-20250135059-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY | 2025-05-01 | — | — | US | claimed |
| US-20250135059-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY | 2025-05-01 | — | — | US | disclosed |
| WO-2025090892-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| CN-111471021-B | Substituted diamino carboxamides and diamino carbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20160039780-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2970172-A1 | BICYCLO [2.2.2]ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-26 | — | — | US | disclosed |
| US-9139534-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2014159802-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159802-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2699553-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2013-01-31 | — | — | US | disclosed |
| WO-2012145569-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | NPSR1 4625/4885CHRM1 4541/4885HSD11B1 4214/4885 |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | NPSR1 1993/4885CHRM1 492/4885HSD11B1 700/4885 |
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | NPSR1 4625/4885CHRM1 4541/4885HSD11B1 4214/4885 |
| US-20150336901-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | NPSR1 4625/4885CHRM1 4541/4885HSD11B1 4214/4885 |
| US-20160039780-A1 | BICYCLO [2.2.2] ACID GPR120 MODULATORS | GPR180, GPR88, GPBAR1 | NPSR1 156/4885CHRM1 666/4885HSD11B1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.